Post-therapeutic Relapse of Psoriasis After CD11a Blockade is Associated with T Cells and Inflammatory Myeloid DCs

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Feb 21

PMID 22348003

Citations 14

Authors

Leanne M Johnson-Huang

Cara A Pensabene

Kejal R Shah

Katherine C Pierson

Toyoko Kikuchi

Tim Lentini

Patricia Gilleaudeau

Mary Sullivan-Whalen

Inna Cueto

Artemis Khatcherian

Luke A Hyder

Mayte Suarez-Farinas

James G Krueger

Michelle A Lowes

Affiliations

Soon will be listed here.

Abstract

Unlabelled: To understand the development of new psoriasis lesions, we studied a group of moderate-to-severe psoriasis patients who experienced a relapse after ceasing efalizumab (anti-CD11a, Raptiva, Genentech). There were increased CD3(+) T cells, neutrophils, CD11c(+) and CD83(+) myeloid dendritic cells (DCs), but no increase in CD1c(+) resident myeloid DCs. In relapsed lesions, there were many CD11c(+)CD1c(-), inflammatory myeloid DCs identified by TNFSF10/TRAIL, TNF, and iNOS. CD11c(+) cells in relapsed lesions co-expressed CD14 and CD16 in situ. Efalizumab induced an improvement in many psoriasis genes, and during relapse, the majority of these genes reversed back to a lesional state. Gene Set Enrichment Analysis (GSEA) of the transcriptome of relapsed tissue showed that many of the gene sets known to be present in psoriasis were also highly enriched in relapse. Hence, on ceasing efalizumab, T cells and myeloid cells rapidly enter the skin to cause classic psoriasis.

Trial Registration: Clinicaltrials.gov NCT00115076.

Citing Articles

Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease.

Fang X, Song J, Zhou K, Zi X, Sun B, Bao H Molecules. 2023; 28(15).

PMID: 37570615 PMC: 10419790. DOI: 10.3390/molecules28155645.

Bioinformatic Analysis and Translational Validation of Psoriasis Candidate Genes for Precision Medicine.

Li A, Li W, Yu X, Zhang D, Liu Y, Li D Clin Cosmet Investig Dermatol. 2022; 15:1447-1458.

PMID: 35924255 PMC: 9343179. DOI: 10.2147/CCID.S378143.

Climatotherapy at the Dead Sea for psoriasis is a highly effective anti-inflammatory treatment in the short term: An immunohistochemical study.

Emmanuel T, Petersen A, Houborg H, Ronsholdt A, Lybaek D, Steiniche T Exp Dermatol. 2022; 31(8):1136-1144.

PMID: 35196397 PMC: 9541097. DOI: 10.1111/exd.14549.

T-Cell Adhesion in Healthy and Inflamed Skin.

Moreau J, Gouirand V, Rosenblum M JID Innov. 2022; 1(2):100014.

PMID: 35024681 PMC: 8669513. DOI: 10.1016/j.xjidi.2021.100014.

Human CLA Memory T Cell and Cytokines in Psoriasis.

de Jesus-Gil C, Sans-de San Nicolas L, Garcia-Jimenez I, Ferran M, Pujol R, Santamaria-Babi L Front Med (Lausanne). 2021; 8:731911.

PMID: 34778294 PMC: 8585992. DOI: 10.3389/fmed.2021.731911.

References

Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles K, Tian S, Cardinale I . Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2010; 131(3):677-87. DOI: 10.1038/jid.2010.340. View

Gordon K, Feldman S, Koo J, Menter A, Rolstad T, Krueger G . Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005; 141(1):82-4. DOI: 10.1001/archderm.141.1.82. View

Vugmeyster Y, Kikuchi T, Lowes M, Chamian F, Kagen M, Gilleaudeau P . Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol. 2004; 113(1):38-46. DOI: 10.1016/j.clim.2004.06.001. View

Fuentes-Duculan J, Suarez-Farinas M, Zaba L, Nograles K, Pierson K, Mitsui H . A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol. 2010; 130(10):2412-22. PMC: 2939947. DOI: 10.1038/jid.2010.165. View

Kothary N, Diak I, Brinker A, Bezabeh S, Avigan M, Dal Pan G . Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011; 65(3):546-551. DOI: 10.1016/j.jaad.2010.05.033. View

Nograles K, Zaba L, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, Cardinale I . Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008; 159(5):1092-102. PMC: 2724264. DOI: 10.1111/j.1365-2133.2008.08769.x. View

Chamian F, Lowes M, Lin S, Lee E, Kikuchi T, Gilleaudeau P . Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005; 102(6):2075-80. PMC: 545584. DOI: 10.1073/pnas.0409569102. View

Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L . Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 2008; 29(3):497-510. PMC: 2688399. DOI: 10.1016/j.immuni.2008.07.013. View

Kryczek I, Bruce A, Gudjonsson J, Johnston A, Aphale A, Vatan L . Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008; 181(7):4733-41. PMC: 2677162. DOI: 10.4049/jimmunol.181.7.4733. View

10.

Lowes M, Turton J, Krueger J, Barnetson R . Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol. 2005; 5:9. PMC: 1208875. DOI: 10.1186/1471-5945-5-9. View

11.

Serbina N, Salazar-Mather T, Biron C, Kuziel W, Pamer E . TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity. 2003; 19(1):59-70. DOI: 10.1016/s1074-7613(03)00171-7. View

12.

Serbina N, Kuziel W, Flavell R, Akira S, Rollins B, Pamer E . Sequential MyD88-independent and -dependent activation of innate immune responses to intracellular bacterial infection. Immunity. 2003; 19(6):891-901. DOI: 10.1016/s1074-7613(03)00330-3. View

13.

Suarez-Farinas M, Pellegrino M, Wittkowski K, Magnasco M . Harshlight: a "corrective make-up" program for microarray chips. BMC Bioinformatics. 2005; 6:294. PMC: 1327692. DOI: 10.1186/1471-2105-6-294. View

14.

Zaba L, Fuentes-Duculan J, Steinman R, Krueger J, Lowes M . Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest. 2007; 117(9):2517-25. PMC: 1957542. DOI: 10.1172/JCI32282. View

15.

Seminara N, Gelfand J . Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg. 2010; 29(1):16-9. PMC: 2864916. DOI: 10.1016/j.sder.2010.01.001. View

16.

Schutyser E, Struyf S, Van Damme J . The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003; 14(5):409-26. DOI: 10.1016/s1359-6101(03)00049-2. View

17.

Johnson-Huang L, Suarez-Farinas M, Sullivan-Whalen M, Gilleaudeau P, Krueger J, Lowes M . Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol. 2010; 130(11):2654-63. PMC: 2955161. DOI: 10.1038/jid.2010.166. View

18.

Zaba L, Fuentes-Duculan J, Eungdamrong N, Johnson-Huang L, Nograles K, White T . Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol. 2010; 125(6):1261-1268.e9. PMC: 2910451. DOI: 10.1016/j.jaci.2010.03.018. View

19.

Guttman-Yassky E, Vugmeyster Y, Lowes M, Chamian F, Kikuchi T, Kagen M . Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol. 2008; 128(5):1182-91. DOI: 10.1038/jid.2008.4. View

20.

Capsoni F, Ongari A, Frigerio E, Taglioni M, Altomare G . Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. Int J Immunopathol Pharmacol. 2008; 21(2):437-45. DOI: 10.1177/039463200802100224. View